# Vosoritide: First Approval.

> PubMed lists PMID 34694597 in Drugs as Journal Article, Review, with publication-date metadata of 2021-11 (month precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34694597-vosoritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-02-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34694597-vosoritide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-34694597-vosoritide-v1.json
- Content SHA-256: `5e6745855a11fa9980006bb0648856cce47643f3670ef0fb72335b86c221d6fc`

## Claims and source pins

### Headline

Vosoritide: First Approval. ([`pubmed-observation-pmid-34694597-2022-02-14-9c85d601ee77`](#source-pubmed-observation-pmid-34694597-2022-02-14-9c85d601ee77))

### Summary

PubMed lists PMID 34694597 in Drugs as Journal Article, Review, with publication-date metadata of 2021-11 (month precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34694597-2022-02-14-9c85d601ee77`](#source-pubmed-observation-pmid-34694597-2022-02-14-9c85d601ee77))

### Paragraph 1

PubMed lists PMID 34694597 in Drugs as Journal Article, Review, with publication-date metadata of 2021-11 (month precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34694597-2022-02-14-9c85d601ee77`](#source-pubmed-observation-pmid-34694597-2022-02-14-9c85d601ee77))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34694597-2022-02-14-9c85d601ee77`](#source-pubmed-observation-pmid-34694597-2022-02-14-9c85d601ee77))

## Sources

<a id="source-pubmed-observation-pmid-34694597-2022-02-14-9c85d601ee77"></a>
- **Vosoritide: First Approval. · retained source version 1:2022-02-14:current:9c85d601ee773d20870cbc92fb473185a4051d91a658c2d407a1fb87604a349d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34694597/) (`pubmed-observation-pmid-34694597-2022-02-14-9c85d601ee77`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Vosoritide: First Approval." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-34694597-vosoritide-v1.json SHA-256: 5e6745855a11fa9980006bb0648856cce47643f3670ef0fb72335b86c221d6fc.